Last reviewed · How we verify

BMN 333 — Competitive Intelligence Brief

BMN 333 (BMN 333) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: lysosomal enzyme replacement therapy. Area: Genetics and Rare Diseases.

phase 2 lysosomal enzyme replacement therapy N-acetylgalactosaminidase (NAGLU) Genetics and Rare Diseases Small molecule Live · refreshed every 30 min

Target snapshot

BMN 333 (BMN 333) — BioMarin Pharmaceutical. BMN 333 is a small molecule that targets the enzyme alpha-N-acetylgalactosaminidase (NAGLU), which is deficient in patients with mucopolysaccharidosis type IIIB (MPS IIIB).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BMN 333 TARGET BMN 333 BioMarin Pharmaceutical phase 2 lysosomal enzyme replacement therapy N-acetylgalactosaminidase (NAGLU)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (lysosomal enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMN 333 — Competitive Intelligence Brief. https://druglandscape.com/ci/bmn-333. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: